论文部分内容阅读
呋喃唑酮(Furazolidone)又称痢特灵,是广谱抗菌药物。临床用于治疗细菌性痢疾、伤寒和肠炎等。1972年我国首次报道呋喃唑酮治疗消化性溃疡,以后临床报道逐年增加,同时对喃呋唑酮抗实验性胃溃疡也进行了研究。 一、呋喃唑酮抗实验性胃溃疡作用及其机制 与通常药物研究相反,呋喃唑酮是在临床提示有抗溃疡作用后才进行动物实验验证和机制的研究。 在急性胃溃疡模型中,呋喃唑酮除对应激性溃疡无抑制作用外,对大鼠无水
Furazolidone (Furazolidone), also known as furazolidone, is a broad-spectrum antibacterial drug. Clinically for the treatment of bacterial dysentery, typhoid and enteritis. In 1972, China first reported the treatment of furazolidone peptic ulcer, clinical reports increased year by year, at the same time, furazolidone anti-experimental gastric ulcer were also studied. First, the role of furazolidone on experimental gastric ulcer and its mechanism In contrast to conventional drug research, furazolidone is clinically proven anti-ulcer effect after animal experimental verification and mechanism studies. In acute gastric ulcer model, furazolidone in addition to no inhibitory effect on stress ulcer, the rats without water